| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | SIEGE PHARMACEUTICALS, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R43DK136429 | Evaluating the efficacy of a novel NASH therapeutic | 000 | 1 | NIH | 12/12/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | SIEGE PHARMACEUTICALS, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 000 | 2 | NIH | 5/13/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $298,159 ) |
| | 2023 | 2023 | SIEGE PHARMACEUTICALS INC | 5270 CALIFORNIA AVE | IRVINE | CA | 92617-3231 | ORANGE | USA | R43DK136429 | Evaluating the efficacy of a novel NASH therapeutic | 000 | 1 | NIH | 8/10/2023 | $298,159 |
| | 2023 | 2021 | SIEGE PHARMACEUTICALS INC | 5270 CALIFORNIA AVE | IRVINE | CA | 92617-3231 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 001 | 2 | NIH | 12/1/2022 | $0 |
| | 2023 | 2021 | SIEGE PHARMACEUTICALS, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 000 | 2 | NIH | 11/3/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $989,405 ) |
| | 2021 | 2021 | SIEGE PHARMACEUTICALS, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 001 | 2 | NIH | 6/11/2021 | $989,405 |
| | 2021 | 2020 | SIEGE PHARMACEUTICALS, INC. | 5270 CALIFORNIA AVE STE 300 | IRVINE | CA | 92617-3231 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 000 | 1 | NIH | 12/11/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,008,833 ) |
| | 2020 | 2020 | SIEGE PHARMACEUTICALS, INC. | 93 MURASAKI ST | IRVINE | CA | 92617-4088 | ORANGE | USA | R44CA257568 | Development of synthetic sphingolipids for prostate cancer therapy | 000 | 1 | NIH | 9/24/2020 | $1,008,833 |
|
|
